| 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2024-053 | | --- | --- | --- | | 债券代码: 123109 | 债券简称: 昌红转债 | | 深圳市昌红科技股份有限公司 关于召开 2024 年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2024 年第二次临时股东大会 2、股东大会的召集人：公司董事会。深圳市昌红科技股份有限公司（以下 简称"公司"或"本公司"）董事会于 2024 年 8 月 12 日召开的第六届董事会第十次 会议审议通过了《关于提请召开 2024 年第二次临时股东大会的议案》，同意召开 本次股东大会。 3、会议召开的合法、合规性：本次股东大会会议的召集程序符合有关法律、 行政法规、部门规章、规范性文件和《公司章程》等规定。 4、会议召开的日期、时间： （1）现场会议时间：2024 年 9 月 10 日 14:00 （2）网络投票时间：2024 年 9 月 10 日 通过深圳证券交易所互联网投票系统投票的时间：2024 年 ...

| 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2024-047 | | --- | --- | --- | | 债券代码: 123109 | 债券简称: 昌红转债 | | 深圳市昌红科技股份有限公司 关于 2024 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》的相关规定，深圳市昌红科技股份有限公司（以下简称"昌红科技"或"公 司"）就 2024 年半年度募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）募集资金金额及资金到账时间 1、向不特定对象发行可转换公司债券 经中国证券监督管理委员会《关于同意深圳市昌红科技股份有限公司向不特 定对象发行可转换公司债券注册的批复》（证监许可〔2021〕609 号）同意注册， 公司于 2021 年 4 月 1 日向不特定对象发行了 460.00 万张可转换公司债券，每张 面值 100.00 ...

| 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2024-050 | | --- | --- | --- | | 债券代码: 123109 | 债券简称: 昌红转债 | | 深圳市昌红科技股份有限公司关于使用部分 暂时闲置募集资金及闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 深圳市昌红科技股份有限公司（以下简称"公司"） 于 2024 年 8 月 12 日分 别召开了第六届董事会第十次会议和第六届监事会第十次会议，审议通过了《关 于使用部分暂时闲置募集资金及闲置自有资金进行现金管理的议案》。 一、募集资金基本情况 经中国证券监督管理委员会《关于同意深圳市昌红科技股份有限公司向特定 对象发行股票注册的批复》（证监许可〔2023〕1379 号）同意注册，公司向特定 对象发行 A 股股票 30,000,000 股，每股面值为人民币 1.00 元，发行价格为人民 币 13.79 元/股，募集资金总额为人民币 413,700,000.00 元，扣除不含税的发行费 用人民币 10,081,011.51 元，实际募集资 ...

| 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2024-052 | | --- | --- | --- | | 债券代码: 123109 | 债券简称：昌红转债 | | 深圳市昌红科技股份有限公司 关于新增 2024 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）公司已预计的 2024 年日常关联交易预计情况 2024 年 4 月 25 日，深圳市昌红科技股份有限公司（以下简称"公司"或"昌红 科技"）第六届董事会第八次会议和第六届监事会第八次会议审议通过了《关于 2024 年度日常关联交易预计的议案》，公司及子公司因经营发展及业务运行需要， 预计 2024 年度公司及子公司与关联方发生日常关联交易总金额不超过 2,300.00 万元，主要系向关联方采购商品及接受劳务、销售商品及提供劳务。 具体内容详见公司披露于巨潮资讯网的《关于 2024 年度日常关联交易预计 的公告》（公告编号 2024-022）。 （二）本次增加日常关联交易预计情况 1、因公司及子公司经营发展及业务运行需 ...

| 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2024-051 | | --- | --- | --- | | 债券代码: 123109 | 债券简称：昌红转债 | | 深圳市昌红科技股份有限公司 关于控股子公司部分厂房、宿舍出租的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、出租事项概述 （一）出租事项的基本情况 为提高公司资产的使用效率，在保证公司正常经营的前提下，同意深圳市昌 红科技股份有限公司（以下简称"昌红科技"或"公司"）控股子公司浙江柏明胜医 疗科技有限公司（以下简称"浙江柏明胜"）将位于浙江省绍兴市上虞区杭州湾经 济技术开发区康阳大道 26 号内的部分暂时闲置自有厂房、宿舍出租给公司全资 /控股子公司，出租厂房（含研发办公区）总建筑面积不超过 30,000.00 平方米， 宿舍出租总间数不超过 80 间，年租金不超过 750.00 万元。 （二）审批程序 2024 年 8 月 12 日，公司第六届董事会第十次会议、第六届监事会第十次会 议，审议通过了《关于控股子公司部分厂房、宿舍出租的议案》。关联董事李焕 昌、 ...

中信证券股份有限公司 关于深圳市昌红科技股份有限公司 新增 2024 年度日常关联交易预计的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为深圳市昌红科 技股份有限公司（以下简称"昌红科技"或"公司"）向不特定对象发行可转换公司债 券持续督导阶段的保荐人以及 2022 年度向特定对象发行 A 股股票的保荐人，根据《证 券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律法规规 定，对公司本次拟新增 2024 年度日常关联交易预计的事项进行了核查，具体情况如下： 一、日常关联交易基本情况 2024 年 4 月 25 日，深圳市昌红科技股份有限公司（（以下简称（"公司"或（"昌红科 技"）第六届董事会第八次会议和第六届监事会第八次会议审议通过了《关于 2024 年 度日常关联交易预计的议案》，公司及子公司因经营发展及业务运行需要，预计 2024 年度公司及子公司与关联方发生日常关联交易总金额不超过 2,300.00 万元，主要系向关 联方采购商品及接受劳务、销售商品及提供劳务。 具体内容详见公司 ...

本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市昌红科技股份有限公司（以下简称"公司"）于 2024 年 8 月 12 日召开 第六届董事会第十次会议、第六届监事会第十次会议，审议通过了《关于 2024 年半年度利润分配方案的议案》。现将具体事项公告如下： | 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2024-048 | | --- | --- | --- | | 债券代码: 123109 | 债券简称: 昌红转债 | | 深圳市昌红科技股份有限公司 关于 2024 年半年度利润分配方案的公告 一、2024 年半年度利润分配方案 根据公司 2024 年半年度财务报告（未经审计），公司 2024 年半年度母公司 实现净利润 93,755,929.57 元，计提盈余公积 9,375,592.96 元，未分配利润 85,746,382.08 元。合并报表归属于上市公司股东的净利润为 43,601,055.31 元， 未分配利润 396,670,791.76 元。根据利润分配应以母公司的可供分配利润及合并 财务报表的可供分配利润孰低的原则 ...

| 证券代码: 300151 | 证券简称：昌红科技 | 公告编号：2024-045 | | --- | --- | --- | | 债券代码: 123109 | 债券简称: 昌红转债 | | 深圳市昌红科技股份有限公司 第六届董事会独立董事专门会议第二次会议决议公告 1 二、审议并通过了《关于控股子公司部分厂房、宿舍出租的议案》 本次公司控股子公司出租暂时闲置厂房、宿舍是在确保公司能正常经营的前 提下进行的，不会影响公司其他业务的开展，也不会影响公司的日常经营运作。 本次交易将遵循公平、公正、公开的原则进行，交易价格符合市场定价原则，不 存在损害公司和全体股东利益的情形。因此，对该事项予以认可，同意提交公司 董事会审议。 表决结果：3 票赞成，0 票反对，0 票弃权 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市昌红科技股份有限公司（以下简称"公司"）第六届董事会独立董事专 门会议第二次会议于 2024 年 8 月 12 日上午在公司 1 号会议室以现场结合通讯表 决方式召开。会议应到独立董事 3 名，实到独立董事 3 名，符合相关法律、行政 法规、 ...

Financial Performance - Revenue for the reporting period was 483.40 million yuan, a decrease of 5.94% compared to the same period last year[12] - Net profit attributable to shareholders of the listed company was 43.60 million yuan, an increase of 2.42% compared to the same period last year[12] - Net cash flow from operating activities was 60.71 million yuan, a decrease of 36.01% compared to the same period last year[12] - Total assets at the end of the reporting period were 2.54 billion yuan, a decrease of 0.59% compared to the end of the previous year[12] - Revenue for the reporting period was RMB 483.4 million, a decrease of 5.94% year-over-year[30] - Operating costs decreased by 7.21% to RMB 345.4 million compared to the same period last year[30] - Net cash flow from operating activities decreased by 36.01% to RMB 60.7 million due to reduced sales and revenue[31] - Net cash flow from investing activities decreased by 148.95% to RMB -166.3 million, mainly due to increased investment activities[31] - Medical devices and consumables segment revenue increased by 18.12% to RMB 144.0 million, with a gross margin of 43.47%[32] - Total operating revenue for the first half of 2024 was RMB 483,404,641.80, a decrease of 5.94% compared to RMB 513,942,535.16 in the same period of 2023[134] - Operating costs for the first half of 2024 were RMB 445,716,152.59, a decrease of 6.02% compared to RMB 474,281,469.16 in the same period of 2023[135] - R&D expenses for the first half of 2024 were RMB 25,378,847.93, a decrease of 14.38% compared to RMB 29,640,689.97 in the same period of 2023[135] - Net profit for the first half of 2024 was RMB 42,701,426.81, a decrease of 7.11% compared to RMB 45,968,806.62 in the same period of 2023[135] - Net profit attributable to parent company shareholders increased to 43,601,055.31 RMB, up from 42,572,447.72 RMB in the previous period[136] - Comprehensive income attributable to parent company shareholders decreased to 32,757,465.20 RMB from 52,839,008.68 RMB[136] - Operating income for the parent company decreased to 133,848,695.24 RMB from 152,235,739.37 RMB[137] - Operating profit for the parent company increased significantly to 92,798,190.15 RMB from 40,781,849.07 RMB[138] - Net profit for the parent company rose to 93,755,929.57 RMB from 41,023,258.84 RMB[138] - Research and development expenses decreased to 7,791,021.91 RMB from 8,877,891.27 RMB[138] - Financial expenses decreased to 1,614,167.75 RMB from 2,660,599.04 RMB[138] - Other comprehensive income after tax for the parent company showed a loss of 10,843,590.11 RMB compared to a gain of 10,266,560.96 RMB in the previous period[136] - Basic and diluted earnings per share remained stable at 0.08 RMB[136] - Total comprehensive income for the parent company increased to 93,755,929.57 RMB from 41,023,258.84 RMB[139] - Sales revenue from goods and services in 2024 H1 decreased to 478.89 million yuan from 577.21 million yuan in 2023 H1, a decline of 17.03%[140] - Net cash flow from operating activities in 2024 H1 was 60.71 million yuan, down 36.01% compared to 94.88 million yuan in 2023 H1[140] - Net cash flow from investing activities in 2024 H1 was -166.29 million yuan, a significant decrease from -66.80 million yuan in 2023 H1[141] - Net cash flow from financing activities in 2024 H1 improved to -68.58 million yuan from -152.95 million yuan in 2023 H1[141] - Cash and cash equivalents at the end of 2024 H1 stood at 521.02 million yuan, compared to 372.38 million yuan at the end of 2023 H1[141] - Parent company's sales revenue from goods and services in 2024 H1 dropped to 122.07 million yuan from 206.48 million yuan in 2023 H1, a decrease of 40.88%[142] - Parent company's net cash flow from operating activities in 2024 H1 was 4.50 million yuan, a sharp decline from 58.30 million yuan in 2023 H1[142] - Parent company's net cash flow from investing activities in 2024 H1 improved to -27.54 million yuan from -44.02 million yuan in 2023 H1[143] - Parent company's net cash flow from financing activities in 2024 H1 was -48.12 million yuan, compared to -123.92 million yuan in 2023 H1[143] - Parent company's cash and cash equivalents at the end of 2024 H1 were 272.12 million yuan, up from 133.90 million yuan at the end of 2023 H1[143] Subsidiaries and Business Segments - The company's subsidiaries include Shenzhen Baimingsheng Medical Devices, Zhejiang Baimingsheng Medical Technology, and Liyin Precision Medical Products (Shanghai)[4] - The company's medical device and consumables business includes real-time glucose monitoring, insulin therapy pumps, IVF, microfluidics, and minimally invasive surgical robots[21] - The company's precision mold and OA product production business provides one-stop services from product design to assembly[22] - The company's semiconductor consumables production business is focused on providing solutions for the semiconductor industry[22] - Shenzhen Boming Sheng, a subsidiary, achieved a net profit of 28.56 million yuan with total assets of 364.7 million yuan and revenue of 134.38 million yuan[54] - Desheng Investment, another subsidiary, reported a net profit of 46.83 million yuan with total assets of 410.97 million yuan and revenue of 173.38 million yuan[54] - Zhejiang Boming Sheng, a subsidiary, incurred a net loss of 16.41 million yuan with total assets of 539.36 million yuan and revenue of 6.25 million yuan[54] - The company's subsidiary, Shenzhen Baimingsheng Medical Devices Co., Ltd., incurred rental expenses of 373.31 million yuan for factory buildings, canteens, and dormitories, reducing profits[94] - The company's subsidiary, Shenzhen Baimingsheng Medical Devices Co., Ltd., incurred rental expenses of 229.33 million yuan for factory buildings and dormitories, reducing profits[94] - The company's subsidiary, Zhejiang Boming, signed a strategic cooperation framework agreement with Fresenius Medical Care Deutschland GmbH to expand its business in hemodialysis medical consumables and medical device structural parts[102] Investments and Capital - The company's registered capital increased from 502.50 million yuan to 532.51 million yuan[11] - The company raised RMB 460 million through the issuance of convertible bonds, with RMB 462.89 million cumulatively invested in the expansion of high-end medical device and consumables production lines and working capital[42] - The company raised RMB 413.70 million through a private placement of A shares, with RMB 236.64 million cumulatively invested in the high-end medical device and consumables base in South China, the headquarters base upgrade project, and working capital[43] - The high-end medical device and consumables production line expansion project (Phase I and II) has a cumulative investment of 340.153 million yuan, achieving an investment progress of 104.66%[44] - The high-end medical device and consumables South China base construction project has a cumulative investment of 52.6098 million yuan, with an investment progress of 39.55%[44] - The headquarters base renovation and upgrade project has a cumulative investment of 85.1626 million yuan, with an investment progress of 49.52%[44] - The supplementary working capital project has a cumulative investment of 98.8701 million yuan, achieving an investment progress of 100.24%[44] - The total investment in committed projects is 699.5332 million yuan, with a total investment progress of 82.15%[44] - The company has unused raised funds of 171.9725 million yuan, of which 170.8311 million yuan is used for cash management[49] - The company's entrusted financial management amount is 446.8243 million yuan, with an outstanding balance of 400.1348 million yuan[51] - The company's total investment in the reporting period was RMB 141.06 million, a 27.22% increase compared to the same period last year[39] - The company's credit rating remains AA- with a stable outlook, as per the latest credit rating report[124] - The company's current ratio decreased by 2.95% from 4.40 to 4.27[126] - The company's quick ratio decreased by 5.95% from 3.70 to 3.48[126] - The company's asset-liability ratio decreased slightly by 0.49% from 33.84% to 33.35%[126] - The company's monetary funds decreased from 700,179,360.58 yuan to 521,017,505.29 yuan[128] - The company's accounts receivable increased from 216,395,752.63 yuan to 252,910,071.06 yuan[128] - The company's inventory increased from 144,623,057.31 yuan to 151,696,080.10 yuan[128] - The company's total assets decreased from 2,555,436,436.76 yuan to 2,540,319,473.80 yuan[130] - The company's total liabilities decreased from 864,728,944.63 yuan to 847,229,163.10 yuan[130] - The company's equity attributable to the parent company increased from 1,641,669,572.59 yuan to 1,652,730,736.06 yuan[130] - The company's retained earnings increased from 389,070,760.96 yuan to 396,670,791.76 yuan[130] - Total assets as of June 30, 2024, were RMB 1,971,793,213.20, an increase of 3.61% compared to RMB 1,903,135,714.13 at the end of 2023[132] - Total liabilities as of June 30, 2024, were RMB 616,673,626.36, a slight decrease of 0.15% compared to RMB 617,580,711.41 at the end of 2023[133] - Accounts receivable as of June 30, 2024, were RMB 114,749,322.45, an increase of 33.33% compared to RMB 86,064,501.81 at the end of 2023[132] - Prepayments as of June 30, 2024, were RMB 2,957,795.73, an increase of 292.56% compared to RMB 753,556.76 at the end of 2023[132] - Contract liabilities as of June 30, 2024, were RMB 10,710,234.86, an increase of 148.75% compared to RMB 4,306,088.48 at the end of 2023[133] - Total equity as of June 30, 2024, was RMB 1,355,119,586.84, an increase of 5.41% compared to RMB 1,285,555,002.72 at the end of 2023[133] - Share capital increased by 493.00 million yuan, reaching 532,508,138.00 yuan[144] - Other equity instruments decreased by 2.57 million yuan, totaling 89,091,700.60 yuan[144] - Capital reserve increased by 4.93 million yuan, reaching 532,377,119.10 yuan[144] - Comprehensive income decreased by 10.8 million yuan, totaling 43,590,101.10 yuan[145] - Owner's equity increased by 11.0 million yuan, reaching 1,649,572.59 million yuan[144] - Minority shareholder equity decreased by 8.67 million yuan, totaling 49,037,919.50 million yuan[144] - Total owner's equity increased by 2.38 million yuan, reaching 1,690,707,492.13 million yuan[144] - Profit distribution to owners decreased by 26,625,431.55 million yuan[145] - General risk provision remained unchanged at 0 yuan[145] - Special reserve remained unchanged at 0 yuan[146] - The company's total owner's equity at the beginning of the period was 1,349,175,853.90, with a decrease of 43,837,869.80 during the period[147] - The comprehensive income for the period was 52,839,008.68, contributing to the owner's equity[147] - The company allocated 100,501,591.00 for profit distribution to owners (or shareholders)[148] - The total owner's equity at the end of the period was 1,305,337,984.10[149] - The parent company's owner's equity at the beginning of the period was 1,285,555,002.72, with an increase of 69,564,584.12 during the period[150] - The parent company's comprehensive income for the period was 93,755,929.57[150] - The parent company's owner's equity at the end of the period was 1,355,119,586.84[150] - The company's total owner's equity at the end of the period was RMB 1,355,119,586.84[151] - The company's comprehensive income for the period was RMB 41,023,258.84[153] - The company's total profit distribution to owners (or shareholders) was RMB -100,501,591.00[153] - The company's registered capital is RMB 532,508,027.00[155] - The company's total owner's equity at the beginning of the period was RMB 956,406,731.15[153] - The company's total owner's equity at the end of the period was RMB 909,574,969.83[154] - The company's total capital reserve at the end of the period was RMB 89,091,458,650.28[154] - The company's total undistributed profit at the end of the period was RMB 56,908,644.19[154] - The company's total special reserve at the end of the period was RMB 53,541,163.48[154] - The company's total other comprehensive income at the end of the period was RMB 61,659,844.81[154] Corporate Governance and Shareholder Information - The company's stock is listed on the Shenzhen Stock Exchange under the ticker symbol 300151[6] - The company's registered and office addresses remain unchanged during the reporting period[8] - The company conducted multiple investor relations activities, including online exchanges and on-site visits, to discuss performance and future outlook[61] - The company held its 2024 first extraordinary general meeting with a 42.49% investor participation rate, passing resolutions on revising the Articles of Association and corporate governance systems[63] - The 2023 annual general meeting saw a 47.74% investor participation rate, approving the 2023 annual report, financial statements, and profit distribution plan[63] - The company proposed a cash dividend of 0.6 yuan per 10 shares for the first half of 2024, totaling 31,950,517.86 yuan, representing 100% of the profit distribution[65][66] - The employee stock ownership plan covers 131 employees, including directors, supervisors, and key staff, holding 3,545,400 shares, accounting for 0.67% of the total share capital[67] - Chairman and General Manager Li Huanchang holds 200,400 shares, representing 0.04% of the total share capital[68] - The company's total share capital is 532,508,631 shares, with distributable profits of 85,746,382.08 yuan[65] - The employee stock ownership plan was revised in June 2022, with funds sourced from employee salaries, self-raised funds, and other legal means[67] - The company maintains a robust corporate governance structure, ensuring fair treatment of all shareholders and timely information disclosure[72] - No environmental penalties were incurred during the reporting period, as the company strictly adheres to environmental protection laws and regulations[71] - The company places high importance on employee training and career development, providing various training programs to enhance employee skills and align personal career goals with corporate development[74] - The company has established long-term strategic partnerships with global clients and suppliers, focusing on resource sharing and collaborative supply chain mechanisms[75] - The company is committed to environmental protection and sustainable development, strictly adhering to environmental regulations and standards for waste management[76] - The company's controlling shareholders and related parties have made commitments regarding share lock-up periods, with specific restrictions on share transfers during and after their tenure[77] - The company's major shareholders have committed to avoiding any form of competition with the company and will not engage in any business that competes with the company[77] - The company's controlling shareholders have pledged to cover any potential tax liabilities related to pre-IPO tax benefits if required by tax authorities[78] - The company's controlling shareholders have committed to covering any potential social security and housing fund liabilities from the pre-IPO period if required by relevant authorities[78] - The company's controlling shareholders and directors have committed to increasing their shareholdings by a total of at least 150.568 million yuan, with specific amounts allocated to each individual[78] - The company's controlling shareholder has committed to reducing related-party transactions and ensuring fair business practices[78] - The company's controlling shareholder, Li Huanchang, has committed to avoiding and reducing related-party transactions with Changhong Technology, ensuring fairness and transparency in any unavoidable transactions[79] - Li Huanchang has also pledged to avoid any

华福证券 证券研究报告|公司首次覆盖 2024年07月31日 电子 公司评级 买入（首次评级） 当前价格：15.73元 高端医耗勇立潮头，晶圆载具奋楫争先 ——昌红科技首次覆盖 证券分析师： 杨钟 执业证书编号：S0210522110003 联系人：詹小瑁 请务必阅读报告末页的重要声明 华福证券 投资要件 Ø 公司系国内"工业之母"之精密模具制造领域领航者。模具加工是工业生产中极其重要且不可或缺的特殊基础工艺装备，其质量和精度极大影响 着制件的最终质量，在电子、军工、医疗用品等重要行业中有超过60%～80%的零部件均使用模具加工制作。公司深耕模具制造领域近二十年， 目前已成为中国重点骨干模具企业，其精密模具设计与制造水平处于行业领先地位。公司凭借其深厚的精密模具设计制造能力、精湛的注塑工艺 和高效稳定且高质量输出的一体化/自动化/定制化供应能力，建立起快速完备且能显著减本增效的客户服务机制，并率先打入众多国际国内巨头 客户产业链并获高度认可。 Ø 公司以精密模具业务起家，跨界成为医疗高分子耗材领域冠军企业。随着我国医药行业的快速发展，公司医疗高分子耗材业务下游的体外诊断、 生命科学实验、基因测序等行业快速扩容 ...